DJIA 16,208.17 149.82 0.93%
NASDAQ 4,683.50 47.40 1.02%
S&P 500 1,931.22 17.37 0.91%
market minute promo


company name or ticker

The Anti-Obesity Sector In Q2 Is Not Looking Good

Vivus: Something You Would Want To Know About Qsymia

Vivus- Qsymia Sales Dip From Peak In Previous Week

Orexigen - Contrave Takes Sales Lead In The U.S. - More Sales Still Needed

Arena: Belviq Sales Fall - Belviq Now Outsold By Competition

Why I Found Vivus To Be A Great Investment

Obesity Drugs: Stocks to Watch

Obesity is now considered one of the most serious threats to global health today. To combat this growing pandemic, the Food and Drug Administration has approved four new anti-obesity medications within the past three years. Here is a look at the comparative growth prospects of two of the biotech companies that received the FDA's blessing for their competing diet pills.

Orexigen Therapeutics (OREX) Is Weak On High Volume Today

Orexigen Sales Dip With Holiday But Grab A Bit Of Market Share

Vivus: Qsymia Sales Dip But Gain A Bit In Market Share

See More Articles...